Ornipressin (ornithine-8-vasopressin, POR-8), is a synthetic vasopressin analogue. Ornipressin produces vasoconstriction via vasopressin V1A receptor-mediated vascular smooth muscle cell contraction. Ornipressin is used to control bleeding in surgical practice. It was introduced in 1971, and approved for use in Germany, Switzerland, New Zealand and Australia.

Demoxytocin is a synthetic analog of a peptide hormone oxytocin. The drug possesses higher oxytocin and lower vasopressin activity than oxytocin and is not broken down by leucylaminopeptidase or serum oxytocinase. Demoxytocin is administered as a buccal tablet formulation and is used for the induction of labor in overdue pregnancies, to prevent and treat puerperal mastitis and to promote lactation.

Atosiban (brand name Tractocile) is a competitive antagonist of human oxytocin at receptor level. In rats and guinea pigs, atosiban was shown to bind to oxytocin receptors, to decrease the frequency of contractions and the tone of the uterine musculature, resulting in a suppression of uterine contractions. Atosiban was also shown to bind to the vasopressin receptor, thus inhibiting the effect of vasopressin. Tractocile is indicated to delay imminent pre-term birth in pregnant adult women with: − regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes − a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50% − a gestational age from 24 until 33 completed weeks − a normal foetal heart rate. Atosiban does not have U.S. Food and Drug Administration (FDA) approval for use in the United States.

Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). Buserelin is used for palliative treatment of prostate cancer, and for treatment of endometriosis. Buserelin is also used for infertility treatment to prepare the pituitary gland before starting treatment with gonadotrophins (FSH and LH) to artificially stimulate ovulation.

Avorelin is a superagonist of natural luteinizing-hormone-releasing-hormone. Avorelin has been formulated in high molecular weight polylactic glycolic acid to afford protracted and continuous release of the peptide from subcutaneous implants. Avorelin has been in phase II clinical trials by Mediolanum for the treatment of prostate cancer, breast cancer and endometriosis. However, this research has been discontinued. Adverse events mainly related to androgen suppression (hot flushes, decreased libido and impotence) or the nature of the disease (skeletal pain).

Fluazacort is a synthetic glucocorticoid. It was marketed under tradename Azacortid for the treatment of eczema and psoriasis.

(R)-FK480 is enantiomer of a cholecystokin-type-A (CCK-A) receptor antagonist FK480. Binding of (R)-FK480 to CCK-A is 26 times less potent than (S)-FK480.

Nandrolone cyclohexylpropionate (a derivative of Nandrolone, which is approved by FDA) is an anabolic steroid. Nandrolone cyclohexylpropionate is reported as an ingredient of Sanabolicum in Austria. Sanabolicum is a rarely found version of the anabolic androgenic steroid nandrolone, with a CycloHexylPropionate ester. This modification makes nandrolone more anabolic (muscle building) and less androgenic. Nandrolone cyclohexylpropionate is an androgen receptor agonist.

Resocortol butyrate is a corticosteroid which has a high intrinsic glucocorticoid activity. Its mineralocorticoid and progestational activity is very low. Resocortol butyrate has local and systemic glucocorticoid effects. The expression of these effects depends on the mode of application and the dosage applied. After topical application on the skin, a local anti-inflammatory effect is seen, which is accompanied by a moderate and reversible adrenal suppression at higher doses. After oral administration in dogs few systemic effects were observed. Resocortol butyrate was marketed under the brand name Pruban as the topical cream for the treatment of acute localised moist dermatitis in dogs. It was discontinued.